SCHEMBL16423340

SCHEMBL16423340

O=c1nc(NC[C@H]2CCN(c3ccc(F)cc3)C2)ncn1Cc1ccc(Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.40
▸ NAMPT P43490 1/20 0.39
▸ LMNA P02545 4/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ USP2 O75604 3/20 0.38
▸ CASP1 P29466 3/20 0.38
▸ CASP7 P55210 3/20 0.38
▸ HIF1A Q16665 3/20 0.38
▸ HSD17B10 Q99714 3/20 0.38
▸ CYP1A2 P05177 2/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ HTT P42858 2/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16544632 1.00 MAPT (0.40) MAPTNAMPTLMNAALDH1A1MEN1
SCHEMBL16534724 1.00 MAPT (0.40) MAPTNAMPTLMNAALDH1A1MEN1
SCHEMBL16422632 0.85 CCNA2 (0.42) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL16422633 0.85 CCNA2 (0.42) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL16423109 0.83 MAPT (0.46) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL16434754 0.83 MAPT (0.43) MAPTNAMPTLMNAALDH1A1MEN1
SCHEMBL16422298 0.81 KAT2B (0.41) MAPTNAMPTLMNAMEN1KMT2A
SCHEMBL16422560 0.81 KAT2B (0.41) MAPTNAMPTLMNAMEN1KMT2A
SCHEMBL16422299 0.81 KAT2B (0.41) MAPTNAMPTLMNAMEN1KMT2A
SCHEMBL16422795 0.81 HPGD (0.38) MAPTNAMPTLMNAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2832728-B1 TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR NISSAN CHEMICAL IND LTD (JP) 2018-09-05 — — EP disclosed
US-9403798-B2 Triazinone compound and T-type calcium channel inhibitor NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-08-02 — — US disclosed
US-20150065705-A1 TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR NISSAN CHEMICAL CORPORATION (JP) 2015-03-05 — — US disclosed
EP-2832728-A1 TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR Nissan Chemical Industries, Ltd. (JP) 2015-02-04 — — EP disclosed
CN-104203928-A Triazinone compound and T-type calcium channel inhibitor NISSAN CHEMICAL IND LTD 2014-12-10 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150065705-A1 TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR CACNA1E, CACNA1I, CACNA1G MAPT 627/4885NAMPT 3823/4885LMNA 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback